Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Trial of SH006 Combination Therapy vs Regorafenib in Advanced Hepatocellular Carcinoma
ChiCTR2600120959Phase 3Recruiting
- Sponsor
- Nanjing Tianyinshan Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of SH006 in hepatocellular carcinoma (HCC) (4 arms), sponsored by Nanjing Tianyinshan Hospital. Primary endpoints: Progression-Free Survival (PFS) and Safety Assessment. Started Dec 2025; status: recruiting.
02
Drugs
SH006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600120959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120959.